Elisabetta A Renzoni

List of Publications by Year
in descending order

148 papers	10,708 citations	27035 58 h-index	39744 98 g-index
151 all docs	151 docs citations	151 times ranked	9494 citing authors

#	Article	IF	Citations
1	Shortâ€term lung function changes predict mortality in patients with fibrotic hypersensitivity pneumonitis. Respirology, 2022, 27, 202-208.	1.3	11
2	Integrating Clinical Probability into the Diagnostic Approach to Idiopathic Pulmonary Fibrosis: An International Working Group Perspective. American Journal of Respiratory and Critical Care Medicine, 2022, 206, 247-259.	2.5	15
3	Infliximab therapy in refractory sarcoidosis: a multicenter real-world analysis. Respiratory Research, 2022, 23, 54.	1.4	20
4	CYFRA 21-1 Predicts Progression in Idiopathic Pulmonary Fibrosis: A Prospective Longitudinal Analysis of the PROFILE Cohort. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 1440-1448.	2.5	14
5	The Respiratory Microbiome in Chronic Hypersensitivity Pneumonitis Is Distinct from That of Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 339-347.	2.5	45
6	HLA association with the susceptibility to anti-synthetase syndrome. Joint Bone Spine, 2021, 88, 105115.	0.8	8
7	Serum markers of pulmonary epithelial damage in systemic sclerosisâ€associated interstitial lung disease and disease progression. Respirology, 2021, 26, 461-468.	1.3	30
8	BAL Is Safe and Well Tolerated in Individuals with Idiopathic Pulmonary Fibrosis: An Analysis of the PROFILE Study. American Journal of Respiratory and Critical Care Medicine, 2021, 203, 136-139.	2.5	15
9	Chest radiography or computed tomography for COVID-19 pneumonia? Comparative study in a simulated triage setting. European Respiratory Journal, 2021, 58, 2004188.	3.1	47
10	Telomeres in Interstitial Lung Disease. Journal of Clinical Medicine, 2021, 10, 1384.	1.0	23
11	Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?. European Respiratory Review, 2021, 30, 210026.	3.0	17
12	The curious incident of the cast in the airway. Thorax, 2021, 76, thoraxjnl-2020-216426.	2.7	0
13	Muscle stimulation in advanced idiopathic pulmonary fibrosis: a randomised placebo-controlled feasibility study. BMJ Open, 2021, 11, e048808.	0.8	7
14	Chronic hypersensitivity pneumonitis: real world diagnostic criteria. Current Opinion in Pulmonary Medicine, 2021, 27, 414-421.	1.2	3
15	Sarcoidosis and maligancy: the chicken and the egg?. Current Opinion in Pulmonary Medicine, 2021, 27, 455-462.	1.2	6
16	A Closer Look at the Role of Anti-CCP Antibodies in the Pathogenesis of Rheumatoid Arthritis-Associated Interstitial Lung Disease and Bronchiectasis. Rheumatology and Therapy, 2021, 8, 1463-1475.	1.1	13
17	Disease pathology in fibrotic interstitial lung disease: is it all about usual interstitial pneumonia?. Lancet, The, 2021, 398, 1437-1449.	6.3	32
18	Protecting the vulnerable: SARS-CoV-2 vaccination in immunosuppressed patients with interstitial lung disease. Lancet Respiratory Medicine,the, 2021, 9, 947-949.	5.2	3

#	Article	IF	Citations
19	Pulmonary fibrosis associated with telomereâ€related gene mutations: A complex inheritance. Respirology, 2021, 26, 1098-1100.	1.3	1
20	Role of MUC1 rs4072037 polymorphism and serum KL-6 levels in patients with antisynthetase syndrome. Scientific Reports, 2021, 11, 22574.	1.6	4
21	Granulomatousâ€“lymphocytic interstitial lung disease: an international research prioritisation. ERJ Open Research, 2021, 7, 00467-2021.	1.1	6
22	Interstitial pneumonia with autoimmune features: challenges and controversies. European Respiratory Review, 2021, 30, 210177.	3.0	16
23	Right Ventricular to Left Ventricular Ratio atÂCT Pulmonary Angiogram Predicts Mortality in Interstitial Lung Disease. Chest, 2020, 157, 89-98.	0.4	30
24	Physiological predictors of exertional oxygen desaturation in patients with fibrotic interstitial lung disease. European Respiratory Journal, 2020, 55, 1901681.	3.1	11
25	Cost-effectiveness of ambulatory oxygen in improving quality of life in fibrotic lung disease: preliminary evidence from the AmbOx Trial. European Respiratory Journal, 2020, 55, 1901157.	3.1	7
26	Defining genetic risk factors for scleroderma-associated interstitial lung disease. Clinical Rheumatology, 2020, 39, 1173-1179.	1.0	12
27	Etiology, Risk Factors, and Biomarkers in Systemic Sclerosis with Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2020, 201, 650-660.	2.5	105
28	Outcome of Hospitalization for COVID-19 in Patients with Interstitial Lung Disease. An International Multicenter Study. American Journal of Respiratory and Critical Care Medicine, 2020, 202, 1656-1665.	2.5	171
29	ERS International Congress, Madrid, 2019: highlights from the Interstitial Lung Diseases Assembly. ERJ Open Research, 2020, 6, 00143-2020.	1.1	0
30	Managing Granulomatousâ€“Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. Frontiers in Immunology, 2020, 11, 606333.	2.2	10
31	Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official American Thoracic Society Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e121-e141.	2.5	133
32	Oxygen for interstitial lung diseases. Current Opinion in Pulmonary Medicine, 2020, 26, 464-469.	1.2	7
33	Diagnosis of Hypersensitivity Pneumonitis in Adults: An Official ATS/JRS/ALAT Clinical Practice Guideline. American Journal of Respiratory and Critical Care Medicine, 2020, 202, e36-e69.	2.5	508
34	Efficacy, Safety, and Tolerability of Treatments for Systemic Sclerosis-Related Interstitial Lung Disease: A Systematic Review and Network Meta-Analysis. Journal of Clinical Medicine, 2020, 9, 2560.	1.0	16
35	Progressive fibrosing interstitial lung disease: clinical uncertainties, consensus recommendations, and research priorities. Lancet Respiratory Medicine,the, 2020, 8, 925-934.	5.2	198
36	Interleukin-31 promotes pathogenic mechanisms underlying skin and lung fibrosis in scleroderma. Rheumatology, 2020, 59, 2625-2636.	0.9	33

#	Article	IF	Citations
37	Mixed Ventilatory Defects in Pulmonary Sarcoidosis. Chest, 2020, 158, 2007-2014.	0.4	28
38	The role of CT in case ascertainment and management of COVID-19 pneumonia in the UK: insights from high-incidence regions. Lancet Respiratory Medicine,the, 2020, 8, 438-440.	5.2	74
39	Interaction between the promoter MUC5B polymorphism and mucin expression: is there a difference according to ILD subtype?. Thorax, 2020, 75, 901-903.	2.7	8
40	A Systematically Derived Exposure Assessment Instrument for Chronic Hypersensitivity Pneumonitis. Chest, 2020, 157, 1506-1512.	0.4	33
41	Pleuroparenchymal fibroelastosis in systemic sclerosis: prevalence and prognostic impact. European Respiratory Journal, 2020, 56, 1902135.	3.1	34
42	Pleuroparenchymal Fibroelastosis. A Review of Clinical, Radiological, and Pathological Characteristics. Annals of the American Thoracic Society, 2019, 16, 1351-1359.	1.5	110
43	Longitudinal prediction of outcome in idiopathic pulmonary fibrosis using automated CT analysis. European Respiratory Journal, 2019, 54, 1802341.	3.1	22
44	First patient-centred set of outcomes for pulmonary sarcoidosis: a multicentre initiative. BMJ Open Respiratory Research, 2019, 6, e000394.	1.2	17
45	Systemic Sclerosis Associated Interstitial Lung Disease: A Comprehensive Overview. Seminars in Respiratory and Critical Care Medicine, 2019, 40, 208-226.	0.8	14
46	Bromodomain and Extraterminal (BET) Protein Inhibition Restores Redox Balance and Inhibits Myofibroblast Activation. BioMed Research International, 2019, 2019, 1-11.	0.9	23
47	Clinical trial design for acute exacerbations in idiopathic pulmonary fibrosis: A thorny path. Respirology, 2019, 24, 620-621.	1.3	1
48	Comprehensive Supportive Care for Patients with Fibrosing Interstitial Lung Disease. American Journal of Respiratory and Critical Care Medicine, 2019, 200, 152-159.	2.5	46
49	In patients with idiopathic pulmonary fibrosis the presence of hiatus hernia isÂassociated with disease progression andÂmortality. European Respiratory Journal, 2019, 53, 1802412.	3.1	20
50	Research highlights from the 2018 ERS International Congress: interstitial lung diseases. ERJ Open Research, 2019, 5, 00215-2018.	1.1	5
51	Results of the standard set for pulmonary sarcoidosis: feasibility and multicentre outcomes. ERJ Open Research, 2019, 5, 00094-2019.	1.1	5
52	Oxygen therapy in COPD and interstitial lung disease: navigating the knowns and unknowns. ERJ Open Research, 2019, 5, 00118-2019.	1.1	23
53	Pulmonary fibrosis: Genetic analysis of telomereâ€related genes, telomere length measurementâ€or both?. Respirology, 2019, 24, 97-98.	1.3	8
54	Predicting outcomes in rheumatoid arthritis related interstitial lung disease. European Respiratory Journal, 2019, 53, 1800869.	3.1	121

#	Article	IF	Citations
55	Pulmonary involvement in rheumatoid arthritis. , 2019, , 44-67.		88
56	Year in review 2017: Interstitial lung disease, pulmonary vascular disease and sleep. Respirology, 2018, 23, 421-433.	1.3	0
57	Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. European Journal of Human Genetics, 2018, 26, 765-777.	1.4	21
58	Predicting Outcomes in Idiopathic Pulmonary Fibrosis Using Automated Computed Tomographic Analysis. American Journal of Respiratory and Critical Care Medicine, 2018, 198, 767-776.	2.5	140
59	Prevalence and Effects of Emphysema in Never-Smokers with Rheumatoid Arthritis Interstitial Lung Disease. EBioMedicine, 2018, 28, 303-310.	2.7	51
60	Pulmonary hypertension in interstitial lung disease: Limitations of echocardiography compared to cardiac catheterization. Respirology, 2018, 23, 687-694.	1.3	39
61	Functional associations of pleuroparenchymal fibroelastosis and emphysema with hypersensitivity pneumonitis. Respiratory Medicine, 2018, 138, 95-101.	1.3	52
62	Identification of Diagnostic Criteria for Chronic Hypersensitivity Pneumonitis. An International Modified Delphi Survey. American Journal of Respiratory and Critical Care Medicine, 2018, 197, 1036-1044.	2.5	174
63	Likelihood of pulmonary hypertension in patients with idiopathic pulmonary fibrosis and emphysema. Respirology, 2018, 23, 593-599.	1.3	29
64	Effect of ambulatory oxygen on quality of life for patients with fibrotic lung disease (AmbOx): a prospective, open-label, mixed-method, crossover randomised controlled trial. Lancet Respiratory Medicine,the, 2018, 6, 759-770.	5.2	145
65	New treatment paradigms for connective tissue disease-associated interstitial lung disease. Current Opinion in Pulmonary Medicine, 2018, 24, 453-460.	1.2	10
66	Idiopathic Pleuroparenchymal Fibroelastosis. Current Pulmonology Reports, 2017, 6, 9-15.	0.5	61
67	Hostâ€“Microbial Interactions in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2017, 195, 1640-1650.	2.5	169
68	Antacid Therapy and Disease Progression in Patients with Idiopathic Pulmonary Fibrosis Who Received Pirfenidone. Respiration, 2017, 93, 415-423.	1.2	63
69	Shortâ€Term Pulmonary Function Trends Are Predictive of Mortality in Interstitial Lung Disease Associated With Systemic Sclerosis. Arthritis and Rheumatology, 2017, 69, 1670-1678.	2.9	247
70	Rituximab versus cyclophosphamide for the treatment of connective tissue disease-associated interstitial lung disease (RECITAL): study protocol for a randomised controlled trial. Trials, 2017, 18, 275.	0.7	121
71	Patientâ€reported outcome measures in idiopathic pulmonary fibrosis: <scp>W</scp>here do we stand?. Respirology, 2017, 22, 628-629.	1.3	3
72	British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. Journal of Allergy and Clinical Immunology: in Practice, 2017, 5, 938-945.	2.0	138

#	Article	IF	Citations
73	Effect of pirfenidone on cough in patients with idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1701157.	3.1	61
74	Pleuroparenchymal Fibroelastosis. American Journal of Surgical Pathology, 2017, 41, 1683-1689.	2.1	57
75	Pulmonary Sarcoidosis. Seminars in Respiratory and Critical Care Medicine, 2017, 38, 437-449.	0.8	14
76	Use of Patterned Collagen Coated Slides to Study Normal and Scleroderma Lung Fibroblast Migration. Scientific Reports, 2017, 7, 2628.	1.6	4
77	An epithelial biomarker signature for idiopathic pulmonary fibrosis: an analysis from the multicentre PROFILE cohort study. Lancet Respiratory Medicine,the, 2017, 5, 946-955.	5.2	190
78	Functional and prognostic effects when emphysema complicates idiopathic pulmonary fibrosis. European Respiratory Journal, 2017, 50, 1700379.	3.1	71
79	Ambulatory oxygen in fibrotic lung disease (AmbOx): study protocol for a randomised controlled trial. Trials, 2017, 18, 201.	0.7	17
80	Antacid therapy and disease outcomes in idiopathic pulmonary fibrosis: a pooled analysis. Lancet Respiratory Medicine,the, 2016, 4, 381-389.	5.2	189
81	Daily Home Spirometry: An Effective Tool for Detecting Progression in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2016, 194, 989-997.	2.5	138
82	Cough in idiopathic pulmonary fibrosis. European Respiratory Review, 2016, 25, 278-286.	3.0	82
83	Epigenetic regulation of cyclooxygenase-2 by methylation of c8orf4Âin pulmonary fibrosis. Clinical Science, 2016, 130, 575-586.	1.8	64
84	Anti-acid treatment in patients with IPF: interpret results from post-hoc, subgroup, and exploratory analyses with great caution â€“ Authors' reply. Lancet Respiratory Medicine,the, 2016, 4, e48.	5.2	6
85	Mucins MUC5B and MUC5AC in Distal Airways and Honeycomb Spaces: Comparison among Idiopathic Pulmonary Fibrosis/Usual Interstitial Pneumonia, Fibrotic Nonspecific Interstitial Pneumonitis, and Control Lungs. American Journal of Respiratory and Critical Care Medicine, 2016, 193, 462-464.	2.5	38
86	Cough in interstitial lung disease. Pulmonary Pharmacology and Therapeutics, 2015, 35, 122-128.	1.1	13
87	Rasch analysis and impact factor methods both yield valid and comparable measures of health status in interstitial lung disease. Journal of Clinical Epidemiology, 2015, 68, 1019-1027.	2.4	10
88	Sarcoidosis and Cancer Risk. Chest, 2015, 147, 778-791.	0.4	122
89	Pharmacologic therapies for idiopathic pulmonary fibrosis, past and future. Annals of Medicine, 2015, 47, 100-105.	1.5	26
90	Cyclical caspofungin for chronic pulmonary aspergillosis in sarcoidosis. Thorax, 2014, 69, 287-288.	2.7	28

#	Article	IF	Citations
91	Rituximab in severe, treatmentâ€refractory interstitial lung disease. Respirology, 2014, 19, 353-359.	1.3	217
92	Molecular Biomarkers in Interstitial Lung Diseases. Molecular Diagnosis and Therapy, 2014, 18, 505-522.	1.6	14
93	Pathogenesis of idiopathic pulmonary fibrosis: review of recent findings. F1000prime Reports, 2014, 6, 69.	5.9	30
94	Serum Interleukin 6 Is Predictive of Early Functional Decline and Mortality in Interstitial Lung Disease Associated with Systemic Sclerosis. Journal of Rheumatology, 2013, 40, 435-446.	1.0	226
95	Microarray profiling reveals suppressed interferon stimulated gene program in fibroblasts from scleroderma-associated interstitial lung disease. Respiratory Research, 2013, 14, 80.	1.4	81
96	The minimal important difference of the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) and forced vital capacity in interstitial lung disease. Respiratory Medicine, 2013, 107, 1438-1443.	1.3	39
97	Novel use of rituximab in hypersensitivity pneumonitis refractory to conventional treatment. Thorax, 2013, 68, 780-781.	2.7	52
98	The development and validation of the King's Sarcoidosis Questionnaire for the assessment of health status. Thorax, 2013, 68, 57-65.	2.7	92
99	Mucin 5B promoter polymorphism is associated with idiopathic pulmonary fibrosis but not with development of lung fibrosis in systemic sclerosis or sarcoidosis. Thorax, 2013, 68, 436-441.	2.7	193
100	A rapidly growing lung mass with air crescent formation. Thorax, 2013, 68, 394-395.	2.7	5
101	Respiratory Muscle Fatigue following Exercise in Patients with Interstitial Lung Disease. Respiration, 2013, 85, 220-227.	1.2	13
102	Significance of connective tissue disease features in idiopathic interstitial pneumonia. European Respiratory Journal, 2012, 39, 661-668.	3.1	184
103	The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax, 2012, 67, 804-810.	2.7	180
104	Severe interstitial lung disease in connective tissue disease: rituximab as rescue therapy. European Respiratory Journal, 2012, 40, 641-648.	3.1	123
105	Pleuroparenchymal fibroelastosis: a spectrum of histopathological and imaging phenotypes. European Respiratory Journal, 2012, 40, 377-385.	3.1	335
106	Circulating Biomarkers of Interstitial Lung Disease in Systemic Sclerosis. International Journal of Rheumatology, 2012, 2012, 1-10.	0.9	23
107	Diffuse Cystic Lung Disease of Unexplained Cause With Coexistent Small Airway Disease. American Journal of Surgical Pathology, 2012, 36, 228-234.	2.1	31
108	Morphometric analysis of intralobular, interlobular and pleural lymphatics in normal human lung. Journal of Anatomy, 2012, 220, 396-404.	0.9	31

#	Article	IF	Citations
109	Pulmonary function vascular index predicts prognosis in idiopathic interstitial pneumonia. Respirology, 2012, 17, 674-680.	1.3	23
110	Review Series: Aspects of Interstitial lung disease: Connective tissue disease-associated interstitial lung disease: How does it differ from IPF? How should the clinical approach differ?. Chronic Respiratory Disease, 2011, 8, 53-82.	1.0	142
111	Endothelin in Pulmonary Fibrosis. American Journal of Respiratory Cell and Molecular Biology, 2011, 44, 1-10.	1.4	62
112	Ambulatory oxygen in interstitial lung disease. European Respiratory Journal, 2011, 38, 987-990.	3.1	99
113	Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. European Respiratory Journal, 2010, 35, 830-836.	3.1	313
114	Lymphatic and blood vessels in scleroderma skin, a morphometric analysis. Human Pathology, 2010, 41, 366-374.	1.1	35
115	A Polymorphism in theCTGFPromoter Region Associated with Systemic Sclerosis. New England Journal of Medicine, 2007, 357, 1210-1220.	13.9	185
116	Endogenous endothelin-1 signaling contributes to type I collagen and CCN2 overexpression in fibrotic fibroblasts. Matrix Biology, 2007, 26, 625-632.	1.5	102
117	Endothelin is a downstream mediator of profibrotic responses to transforming growth factor Î² in human lung fibroblasts. Arthritis and Rheumatism, 2007, 56, 4189-4194.	6.7	155
118	Analysis of BTNL2 genetic polymorphisms in British and Dutch patients with sarcoidosis. Tissue Antigens, 2007, 70, 219-227.	1.0	75
119	Increased pulmonary neurotrophin protein expression in idiopathic interstitial pneumonias. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 2007, 24, 13-23.	0.2	21
120	Hammerhead ribozyme-mediated silencing of the mutant fibrillin-1 of tight skin mouse: Insight into the functional role of mutant fibrillin-1. Experimental Cell Research, 2006, 312, 1463-1474.	1.2	4
121	CCN2 Is Necessary for Adhesive Responses to Transforming Growth Factor-Î²1 in Embryonic Fibroblasts. Journal of Biological Chemistry, 2006, 281, 10715-10726.	1.6	140
122	C-C Chemokine Receptor 5 Gene Variants in Relation to Lung Disease in Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2005, 172, 721-728.	2.5	62
123	Activation of Key Profibrotic Mechanisms in Transgenic Fibroblasts Expressing Kinase-deficient Type II Transforming Growth Factor-Î² Receptor (TÎ²RIIÎ”k). Journal of Biological Chemistry, 2005, 280, 16053-16065.	1.6	58
124	Matrix Contraction by Dermal Fibroblasts Requires Transforming Growth Factor-Î²/Activin-Linked Kinase 5, Heparan Sulfate-Containing Proteoglycans, and MEK/ERK. American Journal of Pathology, 2005, 167, 1699-1711.	1.9	127
125	Neovascularization in Idiopathic Pulmonary Fibrosis. American Journal of Respiratory and Critical Care Medicine, 2004, 169, 1179-1180.	2.5	36
126	Organizing Pneumonia: Perilobular Pattern at Thin-Section CT. Radiology, 2004, 232, 757-761.	3.6	182

#	Article	IF	Citations
127	Endothelin-1 Induces Expression of Matrix-associated Genes in Lung Fibroblasts through MEK/ERK. Journal of Biological Chemistry, 2004, 279, 23098-23103.	1.6	150
128	Mapping of the immunodominant T cell epitopes of the protein topoisomerase I. Annals of the Rheumatic Diseases, 2004, 63, 982-987.	0.5	23
129	Endothelin-1 Promotes Myofibroblast Induction through the ETA Receptor via a rac/Phosphoinositide 3-Kinase/Akt-dependent Pathway and Is Essential for the Enhanced Contractile Phenotype of Fibrotic Fibroblasts. Molecular Biology of the Cell, 2004, 15, 2707-2719.	0.9	335
130	The TNF-863A allele strongly associates with anticentromere antibody positivity in scleroderma. Arthritis and Rheumatism, 2004, 50, 558-564.	6.7	62
131	Genetic mutations in surfactant protein C are a rare cause of sporadic cases of IPF. Thorax, 2004, 59, 977-980.	2.7	234
132	Gene expression profiling reveals novel TGFÎ² targets in adult lung fibroblasts. Respiratory Research, 2004, 5, 24.	1.4	110
133	BAL findings in idiopathic nonspecific interstitial pneumonia and usual interstitial pneumonia. European Respiratory Journal, 2003, 22, 239-244.	3.1	151
134	Interstitial Vascularity in Fibrosing Alveolitis. American Journal of Respiratory and Critical Care Medicine, 2003, 167, 438-443.	2.5	172
135	C-C Chemokine Receptor 2 and Sarcoidosis. American Journal of Respiratory and Critical Care Medicine, 2003, 168, 1162-1166.	2.5	103
136	Antioxidant effects of gliclazide, glibenclamide, and metformin in patients with type 2 diabetes mellitus. Current Therapeutic Research, 2002, 63, 411-420.	0.5	28
137	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. Arthritis and Rheumatism, 2000, 43, 1633-1640.	6.7	102
138	Consumption of fresh fruit rich in vitamin C and wheezing symptoms in children. Thorax, 2000, 55, 283-288.	2.7	182
139	Distribution of novel polymorphisms of the interleukin-8 and CXC receptor 1 and 2 genes in systemic sclerosis and cryptogenic fibrosing alveolitis. , 2000, 43, 1633.		3
140	Risk Factors for Early, Persistent, and Late-onset Wheezing in Young Children. American Journal of Respiratory and Critical Care Medicine, 1999, 160, 1617-1622.	2.5	190
141	Differences in parentalâ€•and selfâ€•report of asthma, rhinitis and eczema among Italian adolescents. European Respiratory Journal, 1999, 14, 597.	3.1	64
142	Impact of Parental Smoking on Asthma and Wheezing. Epidemiology, 1999, 10, 692-698.	1.2	71
143	Asthma and respiratory symptoms in 6-7 yr old Italian children: gender, latitude, urbanization and socioeconomic factors. European Respiratory Journal, 1997, 10, 1780-1786.	3.1	103
144	Clinical, laboratory and radiological findings in pulmonary fibrosis with and without connective tissue disease. Clinical Rheumatology, 1997, 16, 570-577.	1.0	15

#	Article	IF	Citations
145	Brief report: Allergological evaluation of children with autism. Journal of Autism and Developmental Disorders, 1995, 25, 327-333.	1.7	22
146	Host-vector system for integration of recombinant DNA into chromosomes of transformable and nontransformable streptococci. Journal of Bacteriology, 1988, 170, 1969-1972.	1.0	34
147	Biomarkers. , 0, , 122-142.		1
148	Genetic testing in interstitial lung disease: An international survey. Respirology, 0, , .	1.3	10